117 related articles for article (PubMed ID: 30626079)
1. Recipient
Nomoto H; Takami A; Espinoza JL; Onizuka M; Kashiwase K; Morishima Y; Fukuda T; Kodera Y; Doki N; Miyamura K; Mori T; Nakao S; Morishita E
Int J Mol Sci; 2019 Jan; 20(1):. PubMed ID: 30626079
[TBL] [Abstract][Full Text] [Related]
2. Toll-like receptor genetic variations in bone marrow transplantation.
Uchino K; Mizuno S; Sato-Otsubo A; Nannya Y; Mizutani M; Horio T; Hanamura I; Espinoza JL; Onizuka M; Kashiwase K; Morishima Y; Fukuda T; Kodera Y; Doki N; Miyamura K; Mori T; Ogawa S; Takami A
Oncotarget; 2017 Jul; 8(28):45670-45686. PubMed ID: 28484092
[TBL] [Abstract][Full Text] [Related]
3. Recipient PTPN22 -1123 C/C genotype predicts acute graft-versus-host disease after HLA fully matched unrelated bone marrow transplantation for hematologic malignancies.
Espinoza JL; Takami A; Onizuka M; Morishima Y; Fukuda T; Kodera Y; Akiyama H; Miyamura K; Mori T; Nakao S;
Biol Blood Marrow Transplant; 2013 Feb; 19(2):240-6. PubMed ID: 23025987
[TBL] [Abstract][Full Text] [Related]
4. The recipient CCR5 variation predicts survival outcomes after bone marrow transplantation.
Horio T; Mizuno S; Uchino K; Mizutani M; Hanamura I; Espinoza JL; Onizuka M; Kashiwase K; Morishima Y; Fukuda T; Kodera Y; Doki N; Miyamura K; Mori T; Takami A
Transpl Immunol; 2017 Jun; 42():34-39. PubMed ID: 28487238
[TBL] [Abstract][Full Text] [Related]
5. Toll-like receptor 1 variation increases the risk of transplant-related mortality in hematologic malignancies.
Uchino K; Mizuno S; Mizutani M; Horio T; Hanamura I; Espinoza JL; Matsuo K; Onizuka M; Kashiwase K; Morishima Y; Fukuda T; Kodera Y; Doki N; Miyamura K; Mori TM; Takami A;
Transpl Immunol; 2016 Sep; 38():60-6. PubMed ID: 27369862
[TBL] [Abstract][Full Text] [Related]
6. Rare Variants in the ADAMTS13 Von Willebrand Factor-Binding Domain Contribute to Pediatric Stroke.
Stoll M; Rühle F; Witten A; Barysenka A; Arning A; Strauss C; Nowak-Göttl U
Circ Cardiovasc Genet; 2016 Aug; 9(4):357-67. PubMed ID: 27412500
[TBL] [Abstract][Full Text] [Related]
7. NKG2D gene polymorphism has a significant impact on transplant outcomes after HLA-fully-matched unrelated bone marrow transplantation for standard risk hematologic malignancies.
Espinoza JL; Takami A; Onizuka M; Sao H; Akiyama H; Miyamura K; Okamoto S; Inoue M; Kanda Y; Ohtake S; Fukuda T; Morishima Y; Kodera Y; Nakao S;
Haematologica; 2009 Oct; 94(10):1427-34. PubMed ID: 19794085
[TBL] [Abstract][Full Text] [Related]
8. A single-nucleotide polymorphism of the Fcγ receptor type IIIA gene in the recipient predicts transplant outcomes after HLA fully matched unrelated BMT for myeloid malignancies.
Takami A; Espinoza JL; Onizuka M; Ishiyama K; Kawase T; Kanda Y; Sao H; Akiyama H; Miyamura K; Okamoto S; Inoue M; Ohtake S; Fukuda T; Morishima Y; Kodera Y; Nakao S;
Bone Marrow Transplant; 2011 Feb; 46(2):238-43. PubMed ID: 20400988
[TBL] [Abstract][Full Text] [Related]
9. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
[TBL] [Abstract][Full Text] [Related]
10. Comparison of graft-versus-host disease-free, relapse-free survival according to a variety of graft sources: antithymocyte globulin and single cord blood provide favorable outcomes in some subgroups.
Inamoto Y; Kimura F; Kanda J; Sugita J; Ikegame K; Nakasone H; Nannya Y; Uchida N; Fukuda T; Yoshioka K; Ozawa Y; Kawano I; Atsuta Y; Kato K; Ichinohe T; Inoue M; Teshima T;
Haematologica; 2016 Dec; 101(12):1592-1602. PubMed ID: 27662017
[TBL] [Abstract][Full Text] [Related]
11. Genetic variants of human granzyme B predict transplant outcomes after HLA matched unrelated bone marrow transplantation for myeloid malignancies.
Espinoza LJ; Takami A; Nakata K; Yamada K; Onizuka M; Kawase T; Sao H; Akiyama H; Miyamura K; Okamoto S; Inoue M; Fukuda T; Morishima Y; Kodera Y; Nakao S;
PLoS One; 2011; 6(8):e23827. PubMed ID: 21886827
[TBL] [Abstract][Full Text] [Related]
12. [IL-18 single nucleotide polymorphisms in hematologic malignancies with HLA matched sibling donor allogeneic hematopoietic stem cell transplantation].
Cai X; Song A; Wang H; Zhang P; Zhang G; Yang F; Wei J; Ma Q; Yan Z; Jiang E; Huang Y; Yang D; Wang M; He Y; Han M; Feng S
Zhonghua Xue Ye Xue Za Zhi; 2014 Mar; 35(3):215-20. PubMed ID: 24666487
[TBL] [Abstract][Full Text] [Related]
13. KIR ligands and prediction of relapse after unrelated donor hematopoietic cell transplantation for hematologic malignancy.
Hsu KC; Gooley T; Malkki M; Pinto-Agnello C; Dupont B; Bignon JD; Bornhäuser M; Christiansen F; Gratwohl A; Morishima Y; Oudshoorn M; Ringden O; van Rood JJ; Petersdorf E;
Biol Blood Marrow Transplant; 2006 Aug; 12(8):828-36. PubMed ID: 16864053
[TBL] [Abstract][Full Text] [Related]
14. The recipient CXCL10 + 1642C>G variation predicts survival outcomes after HLA fully matched unrelated bone marrow transplantation.
Nakata K; Takami A; Espinoza JL; Matsuo K; Morishima Y; Onizuka M; Fukuda T; Kodera Y; Akiyama H; Miyamura K; Mori T; Nakao S;
Clin Immunol; 2013 Feb; 146(2):104-11. PubMed ID: 23291247
[TBL] [Abstract][Full Text] [Related]
15. Prospective study on the behaviour of the metalloprotease ADAMTS13 and of von Willebrand factor after bone marrow transplantation.
Peyvandi F; Siboni SM; Lambertenghi Deliliers D; Lavoretano S; De Fazio N; Moroni B; Lambertenghi Deliliers G; Mannuccio Mannucci P
Br J Haematol; 2006 Jul; 134(2):187-95. PubMed ID: 16846477
[TBL] [Abstract][Full Text] [Related]
16. Role of Genetic Polymorphism of ALDH2 in Hematopoietic Stem Cell Transplantation.
Ugai T; Kanda Y; Morishima Y; Matsuo K
Biol Blood Marrow Transplant; 2017 Aug; 23(8):1374-1380. PubMed ID: 28389253
[TBL] [Abstract][Full Text] [Related]
17. NOD2/CARD15 single nucleotide polymorphism 13 (3020insC) is associated with risk of sepsis and single nucleotide polymorphism 8 (2104C>T) with herpes viruses reactivation in patients after allogeneic hematopoietic stem cell transplantation.
Jaskula E; Lange A; Kyrcz-Krzemien S; Markiewicz M; Dzierzak-Mietla M; Jedrzejczak WW; Czajka P; Mordak-Domagala M; Lange J; Gronkowska A; Nowak J; Warzocha K; Hellmann A; Kowalczyk J; Drabko K; Gozdzik J; Mizia S;
Biol Blood Marrow Transplant; 2014 Mar; 20(3):409-14. PubMed ID: 24345423
[TBL] [Abstract][Full Text] [Related]
18. Genetic variation in donor CTLA-4 regulatory region is a strong predictor of outcome after allogeneic hematopoietic cell transplantation for hematologic malignancies.
Jagasia M; Clark WB; Brown-Gentry KD; Crawford DC; Fan KH; Chen H; Kassim A; Greer JP; Engelhardt BG; Savani BN
Biol Blood Marrow Transplant; 2012 Jul; 18(7):1069-75. PubMed ID: 22178694
[TBL] [Abstract][Full Text] [Related]
19. Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Unrelated Allogeneic Bone Marrow Transplantation Facilitated by the Japan Marrow Donor Program.
Miyamoto T; Fukuda T; Nakashima M; Henzan T; Kusakabe S; Kobayashi N; Sugita J; Mori T; Kurokawa M; Mori SI
Biol Blood Marrow Transplant; 2017 Jun; 23(6):938-944. PubMed ID: 28219836
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcomes of HLA-DPB1 mismatches in 10/10 HLA-matched unrelated donor-recipient pairs undergoing allogeneic stem cell transplant.
Moyer AM; Hashmi SK; Kroning CM; Kremers WK; De Goey SR; Patnaik M; Litzow M; Gastineau DA; Hogan WJ; Jacob EK; Kreuter JD; Wakefield LL; Gandhi MJ
Eur J Haematol; 2017 Sep; 99(3):275-282. PubMed ID: 28632323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
